momelotinib
Phase 3- Indications
- Myelofibrosis
Company intelligence / Profile preview
Sierra Oncology
San Mateo, California, United Statessierraoncology.com ↗
- Ownership
- Private
- Employees
- ~109
- Development stage
- Phase 3
01
Overview
Sierra Oncology’s lead drug candidate, momelotinib, demonstrated positive topline results in the MOMENTUM Phase III trial for myelofibrosis. The study met all primary and key secondary endpoints including symptom reduction and transfusion independence. The company planned regulatory submissions based on these results prior to its acquisition by GSK.
- Therapeutic areas
- OncologyHematology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
AstraZeneca AB (in-license of AZD5153 BET inhibitor)Carna Biosciences, Inc. (license agreement for SRA141)CRT Pioneer Fund LPOther licensing partners for pipeline assets.
Beyond the preview
Go deeper on Sierra Oncology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sierra Oncology.